JP2020534030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534030A5 JP2020534030A5 JP2020537053A JP2020537053A JP2020534030A5 JP 2020534030 A5 JP2020534030 A5 JP 2020534030A5 JP 2020537053 A JP2020537053 A JP 2020537053A JP 2020537053 A JP2020537053 A JP 2020537053A JP 2020534030 A5 JP2020534030 A5 JP 2020534030A5
- Authority
- JP
- Japan
- Prior art keywords
- linker
- less
- amino acid
- antibody
- lysine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000005647 linker group Chemical group 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 46
- 239000004472 Lysine Substances 0.000 claims description 20
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 18
- 125000000539 amino acid group Chemical group 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 150000003862 amino acid derivatives Chemical class 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 150000002668 lysine derivatives Chemical class 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 150000003141 primary amines Chemical group 0.000 claims description 10
- 108060008539 Transglutaminase Proteins 0.000 claims description 8
- 230000000813 microbial effect Effects 0.000 claims description 8
- 102000003601 transglutaminase Human genes 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- 102000004225 Cathepsin B Human genes 0.000 claims description 5
- 108090000712 Cathepsin B Proteins 0.000 claims description 5
- 150000008574 D-amino acids Chemical class 0.000 claims description 5
- 150000008575 L-amino acids Chemical class 0.000 claims description 5
- 150000002334 glycols Chemical class 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 3
- QRZUPJILJVGUFF-UHFFFAOYSA-N 2,8-dibenzylcyclooctan-1-one Chemical compound C1CCCCC(CC=2C=CC=CC=2)C(=O)C1CC1=CC=CC=C1 QRZUPJILJVGUFF-UHFFFAOYSA-N 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000010638 Kinesin Human genes 0.000 claims description 3
- 108010063296 Kinesin Proteins 0.000 claims description 3
- 229930126263 Maytansine Natural products 0.000 claims description 3
- 108010090804 Streptavidin Proteins 0.000 claims description 3
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 claims description 3
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 3
- 150000001345 alkine derivatives Chemical class 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229940127093 camptothecin Drugs 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 claims description 3
- 229950009429 exatecan Drugs 0.000 claims description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 239000002596 immunotoxin Substances 0.000 claims description 3
- 229950001474 maitansine Drugs 0.000 claims description 3
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- URYYVOIYTNXXBN-OWOJBTEDSA-N trans-cyclooctene Chemical compound C1CCC\C=C\CC1 URYYVOIYTNXXBN-OWOJBTEDSA-N 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- -1 Acyl trifluoroborate Chemical compound 0.000 claims description 2
- 101800002638 Alpha-amanitin Proteins 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- RXGJTYFDKOHJHK-UHFFFAOYSA-N S-deoxo-amaninamide Natural products CCC(C)C1NC(=O)CNC(=O)C2Cc3c(SCC(NC(=O)CNC1=O)C(=O)NC(CC(=O)N)C(=O)N4CC(O)CC4C(=O)NC(C(C)C(O)CO)C(=O)N2)[nH]c5ccccc35 RXGJTYFDKOHJHK-UHFFFAOYSA-N 0.000 claims description 2
- 241001495137 Streptomyces mobaraensis Species 0.000 claims description 2
- 239000004007 alpha amanitin Substances 0.000 claims description 2
- CIORWBWIBBPXCG-SXZCQOKQSA-N alpha-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 claims description 2
- CIORWBWIBBPXCG-UHFFFAOYSA-N alpha-amanitin Natural products O=C1NC(CC(N)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-UHFFFAOYSA-N 0.000 claims description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960005501 duocarmycin Drugs 0.000 claims description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 2
- 229930184221 duocarmycin Natural products 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 229960001438 immunostimulant agent Drugs 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 229960005502 α-amanitin Drugs 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims 20
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024034922A JP2024081670A (ja) | 2017-09-19 | 2024-03-07 | トランスグルタミナーゼコンジュゲーション方法およびリンカー |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17191825 | 2017-09-19 | ||
| EP17191825.3 | 2017-09-19 | ||
| GB1800878.9 | 2018-01-19 | ||
| GBGB1800878.9A GB201800878D0 (en) | 2018-01-19 | 2018-01-19 | Transglutaminase conjugation method and linker |
| PCT/EP2018/075350 WO2019057772A1 (en) | 2017-09-19 | 2018-09-19 | METHOD FOR CONJUGATING TRANSGLUTAMINASE AND BINDING SEQUENCE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024034922A Division JP2024081670A (ja) | 2017-09-19 | 2024-03-07 | トランスグルタミナーゼコンジュゲーション方法およびリンカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020534030A JP2020534030A (ja) | 2020-11-26 |
| JP2020534030A5 true JP2020534030A5 (https=) | 2021-07-26 |
Family
ID=63678617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537053A Pending JP2020534030A (ja) | 2017-09-19 | 2018-09-19 | トランスグルタミナーゼコンジュゲーション方法およびリンカー |
| JP2024034922A Pending JP2024081670A (ja) | 2017-09-19 | 2024-03-07 | トランスグルタミナーゼコンジュゲーション方法およびリンカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024034922A Pending JP2024081670A (ja) | 2017-09-19 | 2024-03-07 | トランスグルタミナーゼコンジュゲーション方法およびリンカー |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US12128110B2 (https=) |
| EP (1) | EP3684419A1 (https=) |
| JP (2) | JP2020534030A (https=) |
| KR (1) | KR102697329B1 (https=) |
| CN (1) | CN111163809B (https=) |
| AU (1) | AU2018337671B2 (https=) |
| CA (2) | CA3177215A1 (https=) |
| MX (1) | MX2020002995A (https=) |
| NZ (1) | NZ762376A (https=) |
| WO (1) | WO2019057772A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ762376A (en) | 2017-09-19 | 2022-08-26 | Scherrer Inst Paul | Transglutaminase conjugation method and linker |
| EP3865155B1 (en) * | 2020-02-13 | 2022-11-30 | Orano Med | Process for site-specific modification of an antibody |
| AU2021275632A1 (en) | 2020-05-20 | 2023-02-02 | Janssen Biotech, Inc. | Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase |
| JP7787101B2 (ja) * | 2020-05-20 | 2025-12-16 | ヤンセン バイオテツク，インコーポレーテツド | グリコシル化Ｆｃドメインを含むタンパク質の部位特異的コンジュゲーションのための方法 |
| KR20230069211A (ko) * | 2020-09-18 | 2023-05-18 | 아라리스 바이오테크 아게 | 아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법 |
| CN116801910A (zh) * | 2020-10-25 | 2023-09-22 | 阿拉里斯生物技术股份公司 | 生产抗体-接头偶联物的手段和方法 |
| KR20230096052A (ko) | 2020-10-25 | 2023-06-29 | 아라리스 바이오테크 아게 | 항체-링커 접합체를 생성하기 위한 수단 및 방법 |
| KR20230142455A (ko) * | 2020-11-30 | 2023-10-11 | 앤비션 에스.알.엘. | 항체 단편으로 수식되고 세포독성 물질이 탑재된 다중특이인간 알부민 나노입자 |
| US20230201364A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
| WO2023281480A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
| EP4366781A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| AU2022306974A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| US20230201365A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Modified cd20 antibodies and uses thereof |
| CA3234692A1 (en) * | 2021-09-30 | 2023-04-06 | Ajinomoto Co., Inc. | Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound used in production of the same or salts thereof |
| WO2023072934A1 (en) | 2021-10-25 | 2023-05-04 | Araris Biotech Ag | Methods for producing antibody-linker conjugates |
| JP2025505835A (ja) * | 2022-02-22 | 2025-02-28 | アーデーセー セラピューティクス ソシエテ アノニム | トリミングされたｎ－グリカンを含むｆｃ領域でのトランスグルタミナーゼを伴うコンジュゲーション方法 |
| KR20240150807A (ko) | 2022-02-22 | 2024-10-16 | 아라리스 바이오테크 아게 | 2개 이상의 페이로드를 포함하는 펩티드 링커 |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| US20250179210A1 (en) | 2022-03-09 | 2025-06-05 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
| US20250304927A1 (en) * | 2022-05-20 | 2025-10-02 | Curie Co. Inc. | Pro-peptide variants for modulating activity of transglutaminases |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| US20240424127A1 (en) | 2023-01-11 | 2024-12-26 | Bright Peak Therapeutics Ag | Il-7 polypeptides, immunocytokines comprising same, and uses thereof |
| WO2024210154A1 (ja) * | 2023-04-04 | 2024-10-10 | 味の素株式会社 | 抗体および機能性物質のコンジュゲート、抗体誘導体ならびに化合物、またはそれらの塩 |
| CN121604979A (zh) | 2023-05-23 | 2026-03-03 | 上海联进生物科技有限公司 | 包含效应分子的pd-l1和trop-2靶向缀合物及其用途 |
| EP4673182A1 (en) * | 2023-06-04 | 2026-01-07 | Araris Biotech AG | Dual payload antibody drug conjugates for the treatment of cancer |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025041102A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Targeted immune activation with il-18 immunocytokines |
| WO2025082990A1 (en) | 2023-10-15 | 2025-04-24 | Araris Biotech Ag | Antibody-drug conjugates using two different types of topoisomerase i inhibitors |
| WO2025242909A1 (en) | 2024-05-24 | 2025-11-27 | Paul Scherrer Institut | CD30-targeting antibody-radioligand conjugates and their therapeutic use |
| WO2026013234A1 (en) | 2024-07-10 | 2026-01-15 | Araris Biotech Ag | Triple-payload antibody-drug conjugates (adcs) |
| EP4684803A1 (en) | 2024-07-25 | 2026-01-28 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Antibody conjugated chemical inducers of degradation of rbm39 and therapeutic uses thereof |
| WO2026069134A1 (en) | 2024-09-26 | 2026-04-02 | Bright Peak Therapeutics Ag | Human therapy with il-18 immunocytokines |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| WO1994012520A1 (en) * | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| NZ334148A (en) | 1996-08-12 | 2001-12-21 | Celgene Corp | 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels |
| US5969516A (en) | 1997-07-25 | 1999-10-19 | Ntc, Inc. | Electrical circuit interrupter device locator |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| EP1499885B1 (en) | 2001-08-01 | 2009-10-21 | Cellomics, Inc. | Novel fusion proteins and assays for molecular binding |
| US6660510B2 (en) | 2001-12-17 | 2003-12-09 | Food Industry Research And Development | Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom |
| EP2289942B1 (en) | 2002-04-10 | 2013-07-31 | Genentech, Inc. | Anti-HER2 antibody variants |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| DK1599278T3 (da) | 2003-01-17 | 2011-07-18 | Danisco | Fremgangsmåde til fremstilling af en hydroxysyreester |
| US7955814B2 (en) | 2003-01-17 | 2011-06-07 | Danisco A/S | Method |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| AU2008215422B2 (en) | 2007-02-15 | 2011-07-14 | Ajinomoto Co., Inc. | Transglutaminase having disulfide bond introduced therein |
| US20100087371A1 (en) | 2007-02-22 | 2010-04-08 | Sean Hu | Transglutaminase Variants with Improved Specificity |
| PE20090943A1 (es) | 2007-07-16 | 2009-08-05 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados |
| WO2009072004A2 (en) | 2007-09-26 | 2009-06-11 | Gemin X Pharmaceuticals Canada, Inc. | Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| KR101607346B1 (ko) | 2008-01-31 | 2016-03-29 | 제넨테크, 인크. | 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법 |
| ES2784829T3 (es) | 2009-04-08 | 2020-10-01 | Faulstich Heinz Dr | Componentes de unión a la superficie de células terapéuticas provistos de amatoxina diseñados para terapia de tumores |
| AU2010234335A1 (en) | 2009-04-08 | 2011-10-13 | Deutsches Krebsforschungszentrum | Amatoxin-armed target-binding moieties for the treatment of cancer |
| WO2011077388A1 (en) | 2009-12-22 | 2011-06-30 | Lifebond Ltd | Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices |
| WO2013040142A2 (en) | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| AR082886A1 (es) | 2010-09-03 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones farmaceuticas que los contienen |
| MX347954B (es) | 2010-09-29 | 2017-05-19 | Agensys Inc | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. |
| ES2402254T3 (es) | 2010-09-30 | 2013-04-30 | Heidelberg Pharma Ag | Conjugados de amatoxinas con ligadores mejorados |
| CA2813411C (en) * | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
| WO2013049830A2 (en) * | 2011-09-30 | 2013-04-04 | The Washington University | Tip-1 and grp-78 binding peptides and method of identifying peptide receptors |
| EP2793947B1 (en) | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
| US10132799B2 (en) * | 2012-07-13 | 2018-11-20 | Innate Pharma | Screening of conjugated antibodies |
| EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
| CN105517577A (zh) * | 2013-06-21 | 2016-04-20 | 先天制药公司 | 多肽的酶促偶联 |
| WO2015015448A2 (en) | 2013-07-31 | 2015-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
| EP3055304A1 (en) | 2013-10-09 | 2016-08-17 | Eli Lilly and Company | Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors |
| US11376333B2 (en) | 2013-12-23 | 2022-07-05 | Covalab | mTG substrates for covalent conjugation of compounds |
| PT3134127T (pt) | 2014-04-25 | 2020-04-09 | Rinat Neuroscience Corp | Conjugados de anticorpo-fármaco com alta carga de fármaco |
| WO2015191883A1 (en) | 2014-06-12 | 2015-12-17 | Dophen Biomedical | Homogenous antibody drug conjugates via enzymatic methods |
| PL3185908T3 (pl) | 2014-08-28 | 2020-09-07 | Pfizer Inc. | Łączniki modulujące stabilność do stosowania z koniugatami przeciwciało-lek |
| WO2016100735A1 (en) | 2014-12-19 | 2016-06-23 | Roche Nimblegen, Inc. | Microbial transglutaminases, substrates therefor and methods for the use thereof |
| EP3256166A1 (en) | 2015-02-09 | 2017-12-20 | NBE Therapeutics AG | Maytansine-drug conjugates of her- 2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation |
| JP2018510864A (ja) | 2015-03-10 | 2018-04-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体 |
| EP3069734A1 (en) | 2015-03-17 | 2016-09-21 | Exiris S.r.l. | Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers |
| EP3313523A2 (en) * | 2015-06-23 | 2018-05-02 | Bayer Pharma Aktiengesellschaft | Targeted conjugates of ksp inhibitors |
| ES2855998T3 (es) | 2015-08-07 | 2021-09-27 | Merck Patent Gmbh | Etiqueta transglutamina para bioconjugación específica de sitio eficiente |
| TWI727380B (zh) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| UA124622C2 (uk) | 2015-12-18 | 2021-10-20 | ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. | Кон'юговані імуноглобуліни з c-кінцевим лізином |
| EP3272864A1 (en) | 2016-07-20 | 2018-01-24 | Paul Scherrer Institut | Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation |
| BR112019005964A2 (pt) * | 2016-09-27 | 2019-06-18 | Epicentrx, Inc. | proteínas de fusão imunomoduladoras |
| KR20230008269A (ko) | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| NZ762376A (en) | 2017-09-19 | 2022-08-26 | Scherrer Inst Paul | Transglutaminase conjugation method and linker |
| MX2020004381A (es) | 2017-10-27 | 2020-08-20 | Pfizer | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos. |
| CA3128571A1 (en) | 2019-03-19 | 2020-09-24 | Paul Scherrer Institut | Transglutaminase conjugation method with a glycine based linker |
| KR20230069211A (ko) | 2020-09-18 | 2023-05-18 | 아라리스 바이오테크 아게 | 아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법 |
| KR20230096052A (ko) | 2020-10-25 | 2023-06-29 | 아라리스 바이오테크 아게 | 항체-링커 접합체를 생성하기 위한 수단 및 방법 |
-
2018
- 2018-09-19 NZ NZ762376A patent/NZ762376A/en unknown
- 2018-09-19 EP EP18773746.5A patent/EP3684419A1/en active Pending
- 2018-09-19 AU AU2018337671A patent/AU2018337671B2/en active Active
- 2018-09-19 JP JP2020537053A patent/JP2020534030A/ja active Pending
- 2018-09-19 CN CN201880060599.4A patent/CN111163809B/zh active Active
- 2018-09-19 CA CA3177215A patent/CA3177215A1/en active Pending
- 2018-09-19 KR KR1020207011370A patent/KR102697329B1/ko active Active
- 2018-09-19 MX MX2020002995A patent/MX2020002995A/es unknown
- 2018-09-19 CA CA3075218A patent/CA3075218A1/en active Pending
- 2018-09-19 US US16/648,636 patent/US12128110B2/en active Active
- 2018-09-19 WO PCT/EP2018/075350 patent/WO2019057772A1/en not_active Ceased
-
2024
- 2024-03-07 JP JP2024034922A patent/JP2024081670A/ja active Pending
- 2024-03-14 US US18/604,709 patent/US20240350656A1/en active Pending
- 2024-10-28 US US18/928,274 patent/US20250161479A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534030A5 (https=) | ||
| JP2022525704A5 (https=) | ||
| JP2025016545A5 (https=) | ||
| CN111163809B (zh) | 转谷氨酰胺酶缀合方法和接头 | |
| JP6310033B2 (ja) | 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法 | |
| CN106795203B (zh) | 用于抗体药物缀合物的稳定性调节接头 | |
| AU2013302270A1 (en) | Peptide-dendrimer conjugates and uses thereof | |
| CA2329754A1 (en) | Peptide composition as immunogen for the treatment of allergy | |
| KR970042553A (ko) | 캠프토테신 유도체 | |
| JP2015524796A5 (ja) | 細胞毒性剤と細胞結合受容体との共役体 | |
| CN115515642A (zh) | 抗cd56抗体-药物偶联物及其在治疗中的用途 | |
| US20230263904A1 (en) | Means and methods for producing antibody-linker conjugates | |
| CN105764530A (zh) | 用于对酮修饰的多肽类进行肟缀合的方法 | |
| US20090155289A1 (en) | Furin-cleavable peptide linkers for drug-ligand conjugates | |
| KR20200056403A (ko) | 신규한 psma-표적화 아마니틴 결합체 | |
| JP2022513684A (ja) | 抗１９１ｐ４ｄ１２抗体薬物コンジュゲートを含む薬学的組成物、およびその使用方法 | |
| WO2023072934A1 (en) | Methods for producing antibody-linker conjugates | |
| US20180028682A1 (en) | Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation | |
| JP2024500922A5 (https=) | ||
| AU2021275541A1 (en) | Liquid formulation of long-acting conjugate of GLP-2 | |
| Hudecz | Manipulation of epitope function by modification of peptide structure: a minireview | |
| CN109414509B (zh) | 使用双特异性抗体的抗体药物偶联物平台 | |
| JP2023542910A5 (https=) | ||
| SK150196A3 (en) | Peptides with immunomodulatory effects, pharmaceutical formulations containing them and their use | |
| NZ779213A (en) | Transglutaminase conjugation method with a glycine based linker |